Literature DB >> 17706409

Role of NT-proBNP and 6MWD in chronic thromboembolic pulmonary hypertension.

Jay Suntharalingam1, Kimberley Goldsmith, Mark Toshner, Natalie Doughty, Karen K Sheares, Rodney Hughes, David Jenkins, Joanna Pepke-Zaba.   

Abstract

BACKGROUND: This study aims to evaluate the role of NT-proBNP and six minute walking distance (6MWD) in the pre- and post-operative assessment of subjects undergoing pulmonary endarterectomy (PEA) for chronic thromboembolic pulmonary hypertension (CTEPH).
METHODS: Subjects undergoing PEA between August 2004 and July 2006 were assessed at baseline and 3 months post-operatively with resting haemodynamics, NT-proBNP and 6MWD.
RESULTS: A number of 111 subjects underwent surgery, of which 102 were included. 15 subjects died before their 3 month assessment. Non-survivors had significantly worse preoperative NT-proBNP and 6MWD (4728 pg/mL vs 1863 pg/mL, p=0.001, 182.4 m vs 263.5 m, p=0.001). Taking pre-operative cut-off values of 1200 pg/mL for NT-proBNP and 345 m for 6MWD, both tests had high negative predictive value for predicting mortality (97.3% and 100%, respectively). Amongst survivors, peri-operative changes in NT-proBNP and 6MWD correlated with changes in total pulmonary resistance (TPR) (r=0.49, p<0.001 and r=-0.46, p<0.001). Post-operatively, both NT-proBNP and 6MWD also correlated with mPAP (r=0.65, p<0.001 and r=-0.50, p<0.001) and PVR (r=0.63, p<0.001 and r=-0.47, p<0.001). The ability of NT-proBNP to predict persistent pulmonary hypertension was significantly confounded by age, but not gender, BMI or renal function.
CONCLUSIONS: Pre-operative evaluation with NT-proBNP and 6MWD helps risk-stratify patients prior to PEA. Post-operatively, both markers correlate with changes in disease burden and right ventricular function. These results suggest that both NT-proBNP and 6MWD offer effective 'bedside' tools for the long term follow up of patients with CTEPH.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17706409     DOI: 10.1016/j.rmed.2007.06.027

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  16 in total

1.  Left ventricular strain and strain rate by 2D speckle tracking in chronic thromboembolic pulmonary hypertension before and after pulmonary thromboendarterectomy.

Authors:  Nicholas Olson; Jason P Brown; Andrew M Kahn; William R Auger; Michael M Madani; Thomas J Waltman; Daniel G Blanchard
Journal:  Cardiovasc Ultrasound       Date:  2010-09-27       Impact factor: 2.062

2.  Population pharmacokinetics and the pharmacokinetic/pharmacodynamic relationship of riociguat in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension.

Authors:  Soundos Saleh; Corina Becker; Reiner Frey; Wolfgang Mück
Journal:  Pulm Circ       Date:  2016-03       Impact factor: 3.017

3.  Cardio-pulmonary MRI for detection of treatment response after a single BPA treatment session in CTEPH patients.

Authors:  Christian Schoenfeld; Jan B Hinrichs; Karen M Olsson; Martin-Alexander Kuettner; Julius Renne; Till Kaireit; Christoph Czerner; Frank Wacker; Marius M Hoeper; Bernhard C Meyer; Jens Vogel-Claussen
Journal:  Eur Radiol       Date:  2018-10-11       Impact factor: 5.315

4.  Pulmonary Thromboendarterectomy for Pulmonary Hypertension Before Considering Transplant.

Authors:  Hannah Kooperkamp; Inder Mehta; David Fary; Michael Bates
Journal:  Ochsner J       Date:  2017

5.  Clinical and haemodynamic evaluation of chronic thromboembolic pulmonary hypertension patients scheduled for pulmonary thromboendarterectomy: Is schistosomiasis hypertension an important confounding factor?

Authors:  Mario Terra-Filho; Marcos Figueiredo Mello; Mônica Silveira Lapa; Ricardo Henrique Oliveira Braga Teixeira; Fábio Biscegli Jatene
Journal:  Clinics (Sao Paulo)       Date:  2010       Impact factor: 2.365

Review 6.  Clinical applications of N-terminal pro B-type natriuretic peptide in heart failure and other cardiovascular diseases.

Authors:  Da-Rong Pu; Jun R Chiong; Qi-chang Zhou
Journal:  Heart Fail Rev       Date:  2010-07       Impact factor: 4.214

Review 7.  Utility of natriuretic peptide testing in the evaluation and management of acute decompensated heart failure.

Authors:  Jun R Chiong; Geoffrey T Jao; Kirkwood F Adams
Journal:  Heart Fail Rev       Date:  2010-07       Impact factor: 4.214

8.  Bosentan or Macitentan Therapy in Chronic Thromboembolic Pulmonary Hypertension?

Authors:  M C J van Thor; L Ten Klooster; R J Snijder; J C Kelder; J J Mager; M C Post
Journal:  Lung       Date:  2019-10-03       Impact factor: 2.584

9.  Efficacy and safety of riociguat in the treatment of chronic thromboembolic pulmonary arterial hypertension: A meta-analysis.

Authors:  Miaofa Ying; Jin Song; Shenglong Gu; Rui Zhao; Mingxing Li
Journal:  Medicine (Baltimore)       Date:  2021-06-04       Impact factor: 1.817

10.  Exercise training improves exercise capacity and quality of life in patients with inoperable or residual chronic thromboembolic pulmonary hypertension.

Authors:  Christian Nagel; Felix Prange; Stefan Guth; Jochen Herb; Nicola Ehlken; Christine Fischer; Frank Reichenberger; Stephan Rosenkranz; Hans-Juergen Seyfarth; Eckhard Mayer; Michael Halank; Ekkehard Grünig
Journal:  PLoS One       Date:  2012-07-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.